Genor Biopharma Holdings Limited
NYSE
Genor Biopharma Holdings Limited's latest marketcap:
As of 06/07/2025, Genor Biopharma Holdings Limited's market capitalization has reached $168.65 M. According to our data, Genor Biopharma Holdings Limited is the 20970th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 168.65 M |
| Revenue (ttm) | 27.96 M |
| Net Income (ttm) | -6,952,175.24 |
| Shares Out | 521.23 M |
| EPS (ttm) | -0.01 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/28/2025 |
Genor Biopharma Holdings Limited's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/07/2025 | HK$1.32 B | 59.23% |
| 12/31/2024 | HK$893.67 M | 49.08% |
| 12/29/2023 | HK$599.44 M | -54.84% |
| 12/30/2022 | HK$1.33 B | -62.64% |
| 12/31/2021 | HK$3.55 B | -63.82% |
| 12/31/2020 | HK$9.82 B |
Company Profile
About Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a biopharmaceutical company specializing in the development and commercialization of oncology and autoimmune drugs. Headquartered in Shanghai, China, the company operates both domestically and internationally.
Key Drug Candidates
- GB242: An infliximab biosimilar for treating rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel diseases.
- GB491 (lerociclib): An oral CDK4/6 inhibitor targeting breast cancer.
- GB492: A stimulator of interferon genes, currently in Phase 1/2 clinical trials for solid tumors.
- GB226: In Phase III trials for cervical cancer and Phase II trials for ASPS and r/r PMBCL.
- GB261: In Phase I/II trials for NHL.
- GB263T: In Phase I/II trials for NSCLC.
- GB221: In Phase III trials for HER2+ metastatic breast cancer.
- GB223, GB241, GB251: Various phases of clinical trials for GCTB, PMO, DLBCL, and HER2+ mBC.
Pre-Clinical Pipeline
The company is also advancing several pre-clinical candidates, including GB262, GB264, GB266, GB267, and GB268, aimed at treating various cancers.
Company Background
Founded in 2007, the company was originally named JHBP (CY) Holdings Limited before rebranding to Genor Biopharma Holdings Limited in June 2021.
Frequently Asked Questions
-
What is Genor Biopharma Holdings Limited's (HKG-6998) current market cap?As of 06/07/2025, Genor Biopharma Holdings Limited (including the parent company, if applicable) has an estimated market capitalization of $168.65 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Genor Biopharma Holdings Limited (HKG-6998) rank globally by market cap?Genor Biopharma Holdings Limited global market capitalization ranking is approximately 20970 as of 06/07/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.